Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3251-3260 Newer>

The Motley Fool November 2, 2006 Rich Duprey	Eisai Profits From Demand The Japanese pharmaceutical reports strong profits on increased demand for Alzheimer's treatment. Investors, take note.
The Motley Fool November 2, 2006 Brian Lawler	Angiotech's Study Troubles The results of recent studies in medical journals have brought the company's forecasts down. Investors, take note.
Chemistry World November 2006 Derek Lowe	Opinion: In the Pipeline Is there a way to kill off bad drug candidates before companies invest valuable time and money and in them?
Pharmaceutical Executive November 1, 2006 Patrick Clinton	Man in a Hurry Bureaucratic? Bayer? Not if you ask Arthur Higgins. In just over two years, the head of Bayer HealthCare has proved that pharma can be a quick and nimble business.
Pharmaceutical Executive November 1, 2006	Roundtable: Deficit Reduction Act As things stand today, the most disruptive, confusing, and impossible-to-comply-with regulations for pharma marketing will be the ones springing from the Deficit Reduction Act of 2005, signed into law by President Bush this past February.
Pharmaceutical Executive November 1, 2006 George Koroneos	Global Style Of the nearly 2,000 submissions, 40 gold and silver winners stand out as benchmarks for design and originality in pharma marketing.
Pharmaceutical Executive November 1, 2006	Unraveling the eSource Industry-wide standards for electronic patient data have long felt like buried treasure. Companies today are getting closer - by way of a tangled map.
Pharmaceutical Executive November 1, 2006 Jill Wechsler	Washington Report: Waiting for Advice Companies are increasingly turning to the Division of Drug Marketing, Advertising and Communication (DDMAC) for opinions on ad materials. That's a good thing. What's bad is that DDMAC has slowed to a crawl.
Pharmaceutical Executive November 1, 2006 Patrick Clinton	From the Editor: Under Revision Here is a closer look at a multi-jurisdiction case that charges 42 pharmaceutical companies with violating various RICO and deceptive-trade-practice acts by artificially inflating the Average Wholesale Price they reported to Medicare.
Pharmaceutical Executive November 1, 2006 Sarah Houlton	Global Report: 'Bout Time The European Union has been late to enter the fight against counterfeiting. Fed up, Parliament has passed a proposal designed to give its countries the nudge they need.
<Older 3251-3260 Newer> Return to current articles.